<DOC>
	<DOCNO>NCT02427750</DOCNO>
	<brief_summary>The present study design evaluate safety immunogenicity trivalent , surface antigen , inactivate influenza vaccine 2 age cohort : 18 ≤60 year ≥61 year . For immunogenicity endpoint antibody response influenza vaccine antigen evaluate mean Single Radial Hemolysis ( SRH ) Hemagglutination Inhibition ( HI ) approximately 21 day post vaccination . The vaccine composition base WHO recommend influenza strain 2015 Southern Hemisphere vaccine , data study intend support use vaccine future influenza season recommend vaccine composition remain .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity Trivalent Influenza Vaccine , Formulation 2015 Southern Hemisphere , When Administered Healthy Adult Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Individuals 18 year age day inform consent . 2 . Individuals voluntarily give write informed consent nature study explain accord local regulatory requirement , prior study entry . 3 . Individuals comply study procedure include followup . 4 . Males females nonchild bear potential female childbearing potential use effective birth control method intend use least 30 day last study vaccination . 1 . Progressive , unstable uncontrolled clinical condition . 2 . Hypersensitivity , include allergy , component vaccine , medicinal product medical equipment whose use foreseen study . 3 . Clinical condition represent contraindication intramuscular vaccination blood drawn . 4 . Abnormal function immune system result : Clinical condition , Systemic administration corticosteroid ( PO/IV/IM ) 14 consecutive day within 90 day prior informed consent , Administration antineoplastic immunomodulating agent radiotherapy within 90 day prior informed consent , 5 . Received immunoglobulin blood product within 180 day prior enrollment . 6 . Received investigational nonregistered medicinal product within 30 day prior enrollment . 7 . Study personnel immediate family household member . 8 . Individuals receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrolment study plan receive vaccine within 28 day study vaccine . 9 . Has behavioral cognitive impairment , psychiatric disease , severe neurological ( especially GuillainBarré syndrome ) , opinion investigator may interfere subject 's ability participate study . 10 . Has serious chronic acute disease ( judgment investigator may interfere result study pose additional risk subject ) include limited : medically significant cancer ( except benign localize skin cancer , cancer remission ≥10 year , localized prostate cancer clinically stable &gt; 2 year without treatment ) , medically significant advanced congestive heart failure ( i.e. , New York Heart Association [ NYHA ] class III IV ) , chronic obstructive pulmonary disease ( ie , Global initiative chronic Obstructive Lung Disease stage III IV ) , autoimmune disease ( include rheumatoid arthritis except Hashimoto 's thyroiditis clinically stable ≥5 year ) , diabetes mellitus type I , poorly control diabetes mellitus type II , advance arteriosclerotic disease , history underlying medical condition major congenital abnormality require surgery , chronic treatment , associate developmental delay ( e.g. , Down 's syndrome ) , acute progressive hepatic disease , acute progressive renal disease , severe asthma . 11 . Has know suspect drug alcohol abuse within past 2 year ; 12 . Has follow within past 6 month : laboratoryconfirmed seasonal pandemic influenza disease , receive seasonal pandemic influenza vaccine , 13 . Has acute chronic infection require systemic antibiotic treatment antiviral therapy within last 7 day ; 14 . Has experience fever ( i.e. , body temperature [ preferably axillary ] ≥38.0°C ) within last 3 day intend study vaccination ; 15 . Has body mass index ( BMI ) &gt; 35 kg/m2 ( BMI calculate divide subject 's weight kilogram subject 's height meter multiply subject 's height meter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>